Replies to post #44229 on Cytodyn Inc (CYDY)

[finesand]

BL, this is not about whether CCR5/Cancer MOA is correct - it surely is verified by many papers and Pestell wrote _the_book_ about it.
AFAIK Pestell was first detailing the very metastasis MOA and CCR5/CCL5 function.

Now this man got fired for cause, as CYDY claims, and nobody knows for sure what is going on.
Until today, we only know one side of the story. Especially you as a lawyer might want to react slower on judgements here.

So what is this all about?
About which company will deliver the CCR5 cancer treatment first, best having a patent in hand.
And this is what is being on the line right now .. in our very opinion.
Plus: Is PRO140 the best drug for this treatment?

Also NP pulling a 'first injection' and alternative pre-clinical for the 8 cancer tests - RUSHING - may not be too wise?
The 8-cancer preclinical, maybe RP was not happy with the data?
Carefully not sharing it and redoing the tests but CYDY pressing him to time the data release with some stock blabla - maybe even pre-sharing the data with some elusive investors in an unethical way?

All speculation today.

GL.

[IndexGuy]

Ok, so my wording was too harsh, although I don't know what you call Dr. Pestell at this point. The only thing that matters to investors is Cytodyn's ability to commercialize a product in a timeline that beats the well funded competition to the finish line in the cancer/mono space.
As much as we need the BLA, BP has long ago decided that our product isn't worth much to their combo treatment. They would have bought and we would have sold if they saw that as a threat. If the cancer stuff that we have been pushing for the last 9 months is going to fall off now that the "world renowned pioneer" of the entire research has been fired for cause, we are left with mono for HIV. That may end up being the standard for treatment in 2025, but we aren't the only ones who think we have the inside track on that. We may very well end up with an approved drug that nobody wants to buy.